This article details how these computational methods have been applied throughout the entire research and development pathway of probiotics, including novel strain identification, formulation and production optimization, and elucidation of complex mechanisms of action in the host, and highlights the emerging frontier of personalized probiotic therapy.
Abstract
The microbiome, as a vast and dynamic community of microbes, is now recognized as a key regulator of host physiology, profoundly influencing health and susceptibility to disease. Accordingly, probiotics are a mainstay of prevention and treatment. But the individual complexity and dynamic specificity of an individual’s microbiome make the previous “one-size-fits-all” research model completely invalid. This review systematically analyzes the applications of artificial intelligence (AI) and machine learning (ML) as transformative computational tools necessary to surmount these challenges. In this article, we detail how these computational methods have been applied throughout the entire research and development pathway of probiotics, including novel strain identification (through multi-omics analysis), formulation and production optimization, and elucidation of complex mechanisms of action in the host. Furthermore, we highlight the emerging frontier of personalized probiotic therapy, demonstrating how AI/ML can be utilized to predict treatment efficacy based on individual host data. The objective of this article is to provide a detailed discourse on the actual and prospective applications of AI and ML in this process, ultimately delineating their revolutionary potential to inform the design of the next generation of probiotics with unprecedented precision, efficacy, and sustainability.
Microbiology has been greatly advanced by the incorporation of Artificial Intelligence (AI) by improving the classification, isolation and detection of microorganisms in several fields where microbial exploration is carried out. With the ability to process large volumes of data from genomic sequences, biochemical profi...
S. A. Aransiola, Adams Husseinat Onyinoyi, Joshua O. Akhigbe et al.· Computational biology and ch...· 0 citations
INTRODUCTION
The effectiveness of some existing antibiotics is being compromised by the ever-rising rate at which antimicrobial resistance develops. Artificial Intelligence (AI) is one of the most significant technological innovations that have become possible through which chemical diversity can be explored, interacti...
Manish Pathak, Akansha Dwivedi· Mini-Reviews in Medical Chem...· 0 citations
Antimicrobial resistance (AMR) has become one of the most urgent threats to global public health, with an estimated 4.95 million deaths associated with bacterial resistance in 2019 alone. Conventional approaches to antibiotic development, resistance detection, and treatment selection are increasingly unable to keep pac...
Mia Carter, Brady Wilson· Journal of Public Health and...· 0 citations
This review discusses how AI can accelerate computational drug discovery, virtual screening (VS), and the repurposing of already-approved medications, and it can also optimize combination therapies through computational simulation.
D. Bhagwat, Sonali A. Chikhalwale, S. Mali et al.· Current pharmaceutical desig...· 0 citations
The findings suggest that the digitalization of the pharmaceutical industry and enhanced AI integration hold promise for developing safer and more effective therapeutic strategies, while also identifying obstacles to their widespread adoption and optimal functionality.
K. C. Panda, B. Ravi Kumar, J. Sruti et al.· Reviews on recent clinical t...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.